Amgen Inc. Files 8-K on Financials
Ticker: AMGN · Form: 8-K · Filed: Feb 4, 2025 · CIK: 318154
Sentiment: neutral
Topics: financial-reporting, results-of-operations
Related Tickers: AMGN
TL;DR
Amgen filed an 8-K on Feb 4, 2025, detailing its financial results and condition.
AI Summary
Amgen Inc. filed an 8-K on February 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report period and filing date both being February 4, 2025. Amgen Inc. is incorporated in Delaware and is in the biological products industry.
Why It Matters
This 8-K filing provides an update on Amgen's financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Amgen Inc. (company) — Registrant
- February 4, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-37702 (filing_id) — Commission File Number
- 95-3540776 (tax_id) — IRS Employer Identification No.
- One Amgen Center Drive (address) — Principal executive offices
- Thousand Oaks (city) — Principal executive offices
- California (state) — Principal executive offices
- 91320-1799 (zip_code) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Amgen Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed on February 4, 2025.
What is Amgen Inc.'s state of incorporation?
Amgen Inc. is incorporated in Delaware.
What is Amgen Inc.'s principal executive office address?
Amgen Inc.'s principal executive office is located at One Amgen Center Drive, Thousand Oaks, California 91320-1799.
What is the SIC code for Amgen Inc.?
The Standard Industrial Classification (SIC) code for Amgen Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,458 words · 6 min read · ~5 pages · Grade level 15.5 · Accepted 2025-02-04 16:05:22
Key Financial Figures
- $0.0001 — ange on which registered Common stock, $0.0001 par value AMGN The Nasdaq Global Select
Filing Documents
- amgn-20250204.htm (8-K) — 43KB
- amgn-20241231earningsrelea.htm (EX-99.1) — 719KB
- amgenlogoa.jpg (GRAPHIC) — 13KB
- 0000318154-25-000005.txt ( ) — 1004KB
- amgn-20250204.xsd (EX-101.SCH) — 3KB
- amgn-20250204_def.xml (EX-101.DEF) — 17KB
- amgn-20250204_lab.xml (EX-101.LAB) — 30KB
- amgn-20250204_pre.xml (EX-101.PRE) — 17KB
- amgn-20250204_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. Fourth Quarter and Full Year 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 4, 2025 , the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2024, and its unaudited financial position as of December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development (R&D) expenses and non-GAAP selling, general and administrative expenses. Reconciliations for such non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the press release. The Company included Free Cash Flow (FCF), which is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. The Company also included Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) for the year ended December 31, 2024, calculated by adding interest expense, provision for income taxes, and depreciation and amortization expense to GAAP net income, and debt leverage ratio, calculated as the ratio of GAAP total debt to EBITDA. The Company believes that this presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial per
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated February 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMGEN INC. Date: February 4, 2025 By: /s/ Peter H. Griffith Name: Peter H. Griffith Title: Executive Vice President and Chief Financial Officer